1 citations
,
July 2021 in “Frontiers in Oncology” This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.
February 2026 in “Journal of the American Academy of Dermatology” Estrogen is not recommended for menopausal hair loss due to insufficient evidence.
December 2025 in “International Journal of Innovative Technologies in Social Science” This review suggests that while estrogen-targeted therapies may improve skin quality in postmenopausal women, systemic risks limit hormone replacement therapies, and more research is needed for localized treatments.
August 2026 in “Cosmoderma” This review identifies sebaceous gland disorders as key indicators of hormonal imbalances, detailing how various hormones affect sebaceous function, and emphasizes a multidisciplinary approach to improve diagnosis and management by integrating endocrine, metabolic, and dermatologic insights.
June 2026 in “Scientific Reports” This study found that systemic testosterone exposure in transgender individuals with XX genotype alters skin biology, increasing androgen and estrogen receptor-positive cells, collagen density, and fibronectin expression while reducing immune cells, which could affect surgical outcomes by promoting a male skin phenotype.